Antibody Drug Conjugate – Molecules Synthesis

We have prepared >20,000 ADC molecules for our customers. In addition, we have also scaled up hundred gram of ADC candidate compounds for further studies.

  • Considerable experience in the synthesis of novel payloads and their analogs.
  • We have a large collection of frequently used linkers in house, including PEG linkers, alkyl linkers, click chemistry linkers, and rigid linkers.
  • We have also assembled a collection of over 30 series of attachment sites.
ADC synthesis, antibody drug conjugate, payload, linker, conjugation

WuXi Biology provides ADC-based in vitro assays and in vivo models:

  • Target validation and antibody binding assay
  • Antibody internalization assay
  • Cell viability assay
  • Bystander killing assay
  • ADCC and ADCP assay
  • CDX and PDX models covering multiple targets (HER2, CLDN18.2, CD30, CD33, BCMA, Trop-2, CD79b, Nectin-4)
Antibody Drug Conjugates, ADC, how does it work video

Target validation and antibody binding assay

ADC - Antibody Binding Assay

Cell viability assay_SK-BR-3

ADC - Cell Viability Assay Cytotoxicity

Antibody internalization assay

ADC - Antibody Internalization Assay

Bystander Killing Assay

Bystander killing occurs when the drug from an ADC is released either from the target cell following
internalization and degradation of the ADC or release of the drug within the extracellular space.

ADC - Bystander effect of Antibody Drug Conjugates
ADC - Bystander effect, cytotoxicity cell viability assay

Antibody-dependent cell-mediated phagocytosis (ADCP)

  • Effector: Macrophage isolated from PBMC of healthy donor
  • Target: SK-BR-3 cell line, labeled with 50 nM CellTrace Violet
  • E:T= 8:1
ADCP - Antibody dependent cell-mediated phagocytosis assay, Antibody-drug conjugates

Cell Cycle

ADCP - Antibody dependent cell-mediated phagocytosis assay, ADCs, cell cycle

Cell Apoptosis

Antibody drug conjugates, ADC, cell apoptosis assay, Annexin V, TDM

in vivo testing of Antibody Drug Conjugates

WuXi Biology provides CDX and PDX models covering multiple targets:

HER2related in vivo models
Cancer type10 models availableTumor growth curve
Breast CancerHCC1954, MDA-MB-468 , BT474 , etc.Yes
Gastric CancerNCI-N87, ST-02-0074 , ST-02-0077, etc. Yes
Ovarian CancerSKOV-3 Yes
CLDN18.2 related CDX model
Cancer typeModel IDTumor growth curve
Gastric CancerNUGC4 Yes
Engineered cell line/model overexpressing hCLDN18.2
Cancer typeModel IDTumor growth curve
Pancreatic CancerCLDN18.2 /MIA PaCa-2, xCLDN18.2 /MIA PaCa-2 Yes
Pancreatic CancerCLDN18.2 /BxPC3on going
Gastric Cancer CLDN18.2 /NCI-N87on going
Note: xCLDN18.2 /MIA PaCa-2was established fromCLDN18.2 /MIA PaCa-2which went through in vivo passage.
CLDN18.2 related PDX models with CLDN18 overexpression
Cancer type13 models availableTumor growth curve
Pancreatic CancerPC-07-0004, PC-07-0033, PC-07-0044, etc.Yes
Gastric Cancer ST-02-0079, ST-02-0318, ST-02-0328, etc.Yes

BCMA related CDX models
Cancer type10 models availableTumor growth curve
MyelomaNCI-H929, OPM-2, MOLP-8, MM.1S, etc. Yes
LymphomaPfeiffer, SU-DHL-6, etc. Yes

CD79b related CDX models
Cancer type 12 models available Tumor growth curve
LymphomaDAUDI, NAMALWA, RAJI, SU-DHL-4, etc. Yes

CD19 related lymphoma CDX models
Cancer type 15 models available Tumor growth curve
LymphomaDAUDI, NAMALWA, RAJI, SU-DHL-4, etc. Yes

CD22 related lymphoma CDX models
Cancer type 13 models available Tumor growth curve
LymphomaDAUDI, NAMALWA, RAJI, SU-DHL-4, etc. Yes
CD37 related lymphoma CDX models
Cancer type 18 models available Tumor growth curve
LymphomaDAUDI, NAMALWA, RAJI, SU-DHL-4, etc. Yes
CD30 related CDX models
Cancer type Model ID Tumor growth curve
LymphomaHUT78, SU-DHL-1 Yes
Liver cancerJHH7 Yes
Lung cancerNCI-H211, NCI-H460 Yes
CD33 related a CDX models
Cancer type Model ID Tumor growth curve
LymphomaU937, RL, DOHH2 Yes
Thyroid cancerFTC-238Yes
Brain cancerU118MG, U87MGYes
Trop-2related TNBC/bladder cancer/pancreas cancer CDX models
Cancer type 19 models available Tumor growth curve
Breast cancerHCC70, MDA-MB-468, HCC1937, etc. Yes
Bladder cancerVMCUB1, HT1376, RT112, HT1197, etc.Yes
Pancreas cancerBxPC-3, Panc02.13, HPAC, CAPAN-1, etc.Yes
Nectin-4related bladder/ breast/pancreas cancer CDX models
Cancer type 13 models available Tumor growth curve
Breast cancerHCC70, BT474, HCC1937, MCF-7, etc. Yes
Bladder cancerHT1376, VMCUB1, HT1197, etc.Yes
Pancreas cancerBxPC-3, PANC04.03, CFPAC-1, etc.Yes
FOLR1 related ovarian/ breast cancer CDX models
Cancer type Model ID Tumor growth curve
Breast CancerT47D, CAL51, HCC1937 Yes
Ovarian cancerOV90, SKOV3, OVCAR3 Yes

FOLH1related prostate cancer CDX models
Cancer type Model ID Tumor growth curve
Prostate cancer22RV1, VCAP, LNCap Yes

Related Resources View All

AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment...

Resource Type: Poster

How Does It Work? | Antibody Drug Conjugates

Resource Type: Video

WuXi AppTec Discovery Services

Resource Type: Brochure

Evaluation of the efficacy of ADC in vitro and in...

Resource Type: Poster

How Diversity In Therapeutic Strategies Is Expanding The Drug Discovery...

Resource Type: White Paper